{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-16T22:43:10.936Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-16. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-16. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-16, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"CDNA\",\n  \"company\": \"CareDx, Inc.\",\n  \"investigation_summary\": \"CareDx reported a standout Q1 2026 with +39% YoY revenue growth and EPS of $0.34 vs $0.13 estimate (+162% beat), alongside an announced Naveris oncology acquisition (up to $260M) and lab products divestiture — all positive catalysts for the shares which are up ~58% YTD off a 52-week low. However, the triggering Form 4 cluster is almost entirely routine annual RSU grants to directors at $0 cost basis; there were NO open-market cash purchases by insiders. The sole executive transaction was CEO John Hanna's scheduled sell of ~22K shares (~$528K) via pre-existing 10b5-1 plan — not bullish signaling. Options flow shows a bearish put/call ratio of 3.67:1 and heavy protective positioning, suggesting informed players are hedging rather than betting on continued upside. At forward P/E ~20x with the stock near its 52-week high ($24.85) after a strong run, the risk/reward for an asymmetric long is poor.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"CareDx (CDNA) is a precision medicine company serving transplant patients through molecular diagnostic testing services (AlloSure Kidney/Heart/Lung, AlloMap Heart, HeartCare), laboratory products for HLA typing and NGS-based surveillance, and digital/patient solutions. The company operates from Brisbane CA with ~761 employees and generated $412.8M in FY2025 TTM revenue with 39% YoY growth as of Q1 2026 ($117.7M quarterly). Medicare represents ~27% of test volume; the pending MolDX LCD revision poses reimbursement risk. The Naveris acquisition (closing Q3 2026) expands CDNA into oncology MRD surveillance via the NavDx blood test for HPV-driven cancers, representing a TAM expansion play in an adjacent market where CDNA has limited current presence.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 528000,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-07-28 (Q2 2026)\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026: EPS $0.34 vs $0.13 estimate (+162%); Q4 2025: EPS $0.12 vs $0.23 est (-47%); Q3 2025: EPS $0.28 vs $0.14 est (+98%) — volatile but recent strong beat\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 2026 earnings release; Naveris deal expected to close Q3 2026; MolDX LCD finalization pending (365-day clock from July 17, 2025)\",\n          \"date_or_window\": \"Q2 2026 / H2 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000033/cdna-20260331.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"AlloSure Plus AI-driven diagnostic platform launch; AlloHeme pivotal data presented at 2025 Tandem Meeting for AML/MDS post-transplant relapse surveillance\",\n          \"date_or_window\": \"2026 pipeline milestones\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/caredx-announces-second-koar-analysis-200500646.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"m&a\",\n          \"description\": \"Naveris acquisition up to $260M (Q3 2026 close) for NavDx oncology MRD test; Lab products divestiture in process — both reshape portfolio toward higher-margin services\",\n          \"date_or_window\": \"H2 2026 / Q3 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/caredx-acquire-naveris-expand-cancer-004103372.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"MolDX draft LCD (DL40058/DL40060) released July 17, 2025 proposes bundled payment and utilization limits for surveillance tests — MACs have up to 365 days to finalize; CPT code repricing risk on AlloSure\",\n          \"date_or_window\": \"Pending finalization by mid-2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm\"\n          ],\n          \"directional_bias\": \"bearish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 20.5,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": 466.875,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": 0.583,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"Forward P/E of ~20x is reasonable for a recently profitable company growing revenue 39%, but the stock at $23.25 vs 52-week high of $24.85 leaves little upside cushion before hitting resistance. FCF yield <1% reflects low cash generation relative to market cap. The EV/EBITDA of 467x is distorted by near-zero EBITDA — company only recently turned operationally profitable (Q1 2026 net income $2.8M). No compelling SOTP gap given lack of analyst targets below consensus.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": \"68.9% gross margin in Q1 2026, relatively stable vs FY2025 — company is scaling operating leverage as revenue grows\",\n      \"net_debt_to_ebitda\": \"Net cash position: $187M cash vs $24.5M debt; strong balance sheet to fund acquisition\",\n      \"balance_sheet_grade\": \"A\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 57.3,\n      \"macd_recent_bullish_cross\": true,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 23.25,\n    \"ytd_return_pct\": 58.49,\n    \"from_52w_high_pct\": 6.4\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-25\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 revenue $412.8M (+39% YoY); ~200K commercial tests performed in 2025 from Brisbane lab; Medicare ~25-27% of test volume and ~46% of testing services revenue; AlloSure Kidney reimbursement rate $2,753 effective Jan 1 2026 via CPT code crosswalk to 0493U; AlloMap Heart at $3,240; pending MolDX LCD (DL40058/DL40060) proposes bundled payment for surveillance setting — could reduce test volumes and revenue per test; ongoing Natera litigation (patent infringement + false advertising countersuit); Natera has been ordered to pay $44.9M damages but collection uncertain; company holds 7 US patents on transplant rejection diagnostics expiring through May 2035\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-04-28\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000033/cdna-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: testing services revenue $91.4M (+47.6% YoY); total revenue $117.7M (+39% YoY); net income $2.8M vs loss of ($10.4M) in Q1 2025; gross margin 68.9%; R&D $21.4M (vs $18.5M Q1 2025); S&M $30.4M (vs $23.0M); G&A $30.5M (vs $22.8M) — operating leverage emerging but opex growing in absolute terms; cash and marketable securities ~$198M vs $24.5M debt; pending divestiture of lab products business announced April 2026; Naveris acquisition agreement signed April 28, 2026 for up to $260M (closing Q3 2026); company recognized $17.7M in prior period revenue from retroactive rate adjustments\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-15\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000036/cdna-20260611.htm\",\n      \"key_takeaways\": [\n        \"June 11, 2026 — multiple Form 4 filings cluster; CEO sold ~$528K via pre-scheduled 10b5-1 plan (adopted Dec 13, 2024); six directors received RSU grants vesting on earlier of one-year anniversary or day before first Annual Meeting after grant date\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-08-21\",\n      \"2026-11-20\"\n    ],\n    \"iv_summary\": \"July 17 expiry (30 DTE) shows ATM-ish strikes with IV ~91-98% for calls and ~102% for puts at the $22.50 strike — elevated compared to typical small-cap diagnostics names; OI on puts notably high vs calls, especially $17.50 put with 16 contracts open interest (deep OTM protection play)\",\n    \"notable_skew_or_flow\": \"Put/call ratio of 3.67:1 is highly unusual and suggests heavy hedging activity — likely from institutional holders reducing directional exposure rather than new bearish bets. Top call OI at $22.50 (50 contracts, near ATM), top put OI at $17.50 (16 contracts) creating a wide range between protection floor and modest upside cap.\"\n  },\n  \"competitive_landscape\": \"CareDx leads the transplant dd-cfDNA market with AlloSure Kidney/Heart/Lung against Natera's Prospera test; in heart transplant surveillance, HeartCare combines AlloMap + AlloSure. Key competitive threat: pending LCD from MolDX could disadvantage CareDx if bundled payment favors competitor tests. In oncology MRD (via Naveris acquisition), CDNA enters a crowded space with Exact Sciences, Guardant Health, Natera (again) already commercializing blood-based cancer surveillance — differentiation via transplant-adjacent clinical relationships is the stated thesis.\",\n  \"key_risks\": [\n    \"MolDX LCD revision risk: draft proposal could impose bundled payment and utilization limits on surveillance tests, reducing volumes\",\n    \"Reimbursement concentration: Medicare ~46% of testing services revenue; any rate cuts directly impact margins\",\n    \"Patent litigation with Natera (both directions): ongoing uncertainty around IP validity and damages collection from the $44.9M verdict\",\n    \"Naveris integration risk: paying up to $260M for a commercial-stage company in oncology MRD where CDNA has no existing commercial infrastructure\",\n    \"CEO insider selling via 10b5-1 at ~$24 indicates willingness to trim positions even near 52-week highs\",\n    \"Highly volatile earnings surprise pattern (Q3 +98%, Q4 -47%, Q1 +162%) makes forward guidance unreliable\"\n  ],\n  \"what_the_market_might_be_missing\": \"The Naveris acquisition thesis may be underpriced — NavDx addresses a specific niche: blood-based HPV-mediated cancer surveillance for patients who already had organ transplants, a patient population CDNA knows intimately from its existing transplant center relationships. If AlloHeme (AML/MDS relapse monitoring post-transplant) receives CMS coverage and AlloSeq cfDNA gains traction internationally under CE mark, the services revenue mix shifts materially toward higher-margin testing. However, these catalysts are 12-18 months out and don't address near-term LCD risk.\",\n  \"anti_signals_present\": [\n    \"concentration\",\n    \"accounting\",\n    \"litigation\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"SEC EDGAR - FY2025 10-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm\"\n    },\n    {\n      \"label\": \"SEC EDGAR - Q1 2026 10-Q\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000033/cdna-20260331.htm\"\n    },\n    {\n      \"label\": \"SEC EDGAR Form 4 — CEO Hanna June 15, 2026 (June 11 sell)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1217234/000178112726000008/xslF345X06/form4-06152026_090627.xml\"\n    },\n    {\n      \"label\": \"SEC EDGAR Form 4 cluster — June 16, 2026 filings (7 directors RSU grants)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1217234/000185560826000003/xslF345X06/form4-06162026_090624.xml\"\n    },\n    {\n      \"label\": \"Yahoo Finance News - Naveris Acquisition April 28, 2026\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/caredx-acquire-naveris-expand-cancer-004103372.html\"\n    },\n    {\n      \"label\": \"Yahoo Finance News — Q1 2026 Earnings Results\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/caredx-announces-first-quarter-2026-200100067.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-16T22:43:49.296Z",
      "raw_content": "<think>The user wants me to score the dossier for CDNA (CareDx) and decide whether to skip or draft a trade idea.\nI need to follow the scoring rubric, risk class, thresholds, anti-signal gates, edge check, and output format strictly.\n\nLet's calculate the score based on the rubric:\nA. SMART-MONEY CLUSTER (max 25):\n- 0 pts: 0 distinct insiders with open-market purchases.\n- 0 pts: CEO not among buyers (CEO sold).\n- 0 pts: CFO not among buyers.\n- 0 pts: total purchases $0.\n- 0 pts: no notable 13F initiation.\n- 0 pts: no politician buy.\n- Penalty: -10 pts? Wait, the rule says \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". Here selling is $528K, buying is $0. So yes, -10 pts. But score can't go below 0 usually, or I'll just put 0. Let's put 0.\nScore A: 0\n\nB. OPTIONS FLOW / UOA (max 10):\n- 0 pts: whale_call_blocks_otm not present.\n- 0 pts: bearish put/call ratio 3.67:1, heavy protective positioning. No bullish IV skew.\n- Penalty: -5 pts if whale_put_blocks_otm >= 2 and bearish bias. Dossier says \"heavy protective positioning\" and \"OI on puts notably high vs calls\". I'll give it 0 or -5. Let's say 0.\nScore B: 0\n\nC. CATALYST (max 25):\n- Earnings within 90 days? Yes, 2026-07-28. But last 4 quarters' EPS surprise > 0%? No, Q4 2025 was -47%. So 0 pts for that.\n- Pending product launch/FDA/contract? AlloSure Plus AI launch, MolHeme data. 5 pts for product? \"AlloSure Plus AI-driven diagnostic platform launch; AlloHeme pivotal data\". Let's give 5 pts.\n- Recent guidance raise? Yes. 5 pts.\n- Quantifiable sector tailwind? Not really.\n- Cap at 25. I'll give it 5 pts for guidance raise + product. Actually, let's be strict: 5 pts for guidance raise. Maybe 5 for product. Total 10.\n\nD. MISPRICING (max 15):\n- Forward P/E 20.5 vs sector median null. Not below.\n- EV/EBITDA 467x. Not below.\n- FCF yield 0.583%. Not >= 7%.\n- SOTP gap null.\n- Score D: 0.\n\nE. QUALITY (max 15):\n- ROIC null.\n- Gross margin expanding? \"68.9% gross margin in Q1 2026, relatively stable vs FY2025\". Not expanding >= 3pp.\n- Net debt/EBITDA: Net cash $187M vs $24.5M debt. Strong balance sheet. But EBITDA is near zero, so ratio is meaningless. I'll give 0 or maybe 2 for net cash position. Let's say 0.\nScore E: 0.\n\nF. MOMENTUM/TECHNICAL (max 10):\n- Above 50DMA and 200DMA: Yes. 3 pts.\n- 12-1 month return positive? YTD +58.49%, beating sector likely. 4 pts.\n- RSI 14 in 40-65: 57.3. Yes. 2 pts.\n- MACD bullish cross: Yes. 1 pt.\nScore F: 10.\n\nTotal Score: ~15.\nWait, let's re-evaluate carefully.\nA: 0\nB: 0\nC: 5 (guidance raise) + 5 (product catalyst) = 10\nD: 0\nE: 0\nF: 10\nTotal: 25.\n\nAnti-signal gates:\n\"concentration\", \"accounting\", \"litigation\" are present in anti_signals_present.\nThe dossier explicitly lists risks: MolDX LCD risk, Medicare concentration, Natera litigation, Naveris integration risk.\nThe anti_signals_present field has \"concentration\", \"accounting\", \"litigation\".\nAccording to rules: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nConcentration: Medicare ~46% of testing services revenue. Customer concentration > 30% gate? Medicare is a payer, not a customer in the traditional sense, but still high concentration risk.\nAccounting: \"accounting\" in anti_signals. The dossier mentions \"company recognized $17.7M in prior period revenue from retroactive rate adjustments\" and \"volatile but recent strong beat\". Also \"accounting irregularities (restatements, auditor changes)\" is the gate. The dossier doesn't explicitly say restatement, but it flags accounting risk.\nLitigation: Natera patent litigation ongoing. \"Pending material litigation (DOJ/SEC enforcement, class action with merit)\". Natera litigation is private, but still a risk.\nGiven the anti-signal gates are present, and the score is very low (25), this is a clear skip.\n\nLet's check the threshold for ASYMMETRIC vs CORE.\nMarket cap is not explicitly given, but \"small-cap diagnostics names\" and \"market_cap ≤ $5B\" likely applies. Actually, CDNA is typically a small/micro cap. I'll classify as \"asymmetric\" or \"core\" doesn't matter much since score < 45.\nScore < 45 -> Skip.\n\nReason for skip: Score is low (25/100) due to zero smart-money buying, bearish options skew, lack of valuation discount, and active anti-signal gates (litigation, reimbursement concentration, accounting volatility). The stock has run up 58% YTD with no clear asymmetric upside, and heavy insider selling at highs negates any bullish setup.\n\nI will output the skip JSON.\nCheck format:\n{\n  \"skip\": true,\n  \"score\": 25,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Score is well below the publish threshold due to zero insider buying, bearish options skew, lack of valuation discount, and active anti-signal gates (litigation, reimbursement concentration). With the stock up 58% YTD and insider selling at highs, the risk/reward for any structure is unfavorable.\"\n}\n\nWait, let's double check the scoring rubric details.\nA: 0\nB: 0\nC: 10\nD: 0\nE: 0\nF: 10\nTotal: 20. I'll stick with 20.\nLet's verify C catalyst: \"recent guidance raise (last 90 days)\" -> 5 pts. \"pending product launch\" -> 5 pts. Total 10. Correct.\nF technical: above 50/200DMA (3) + 12-1 momentum (4) + RSI 40-65 (2) + MACD cross (1) = 10. Correct.\nTotal 20.\n\nAnti-signal gates are present. The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will note that the gates apply.\n\nOne minor thing: The prompt says \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". I'll put 0 for smart_money since it can't go negative usually, or I'll just put 0.\n\nI will generate the skip JSON exactly as requested.\nCheck date rules: Not writing any dates in the skip output, but if I did, they must be 2026+.\nAll good.\nOutput matches requested format.\nProceed. \nLet's quickly review the structure hints: Scout says range_bound_or_income. But the dossier says \"risk/reward for an asymmetric long is poor\" and flags heavy hedging. I'll stick with skip.\nThe score breakdown sums to 20.\nReason is concise.\nReady. \nOutput matches exactly. \nProceeds. \n{\n  \"skip\": true,\n  \"score\": 20,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Score falls well below the publish threshold due to zero insider buying, bearish options skew, lack of valuation discount, and active anti-signal gates (litigation, reimbursement concentration). With the stock up 58% YTD and insider selling at highs, the risk/reward for any structure is unfavorable.\"\n}\nWait, should I adjust the score to be more precise? The rubric says max 100. 20 is fine.\nI will output exactly this JSON.\nOne check: \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\" -> I'll keep smart_money at 0.\nAll good.\nOutput matches. \nProceeds. \n[Final Check of the Prompt]\n\"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object. Leave the others null/omitted.\" -> Not applicable since skipping.\n\"IF YOU SKIP — output exactly: { ... }\"\nDone. \nOutput generation. \n(Self-Correction/Refinement during thought)\nWait, the prompt says: \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". I'll just set smart_money to 0. It's fine.\nThe score is 20.\nI will produce the JSON. \nAll constraints met. \nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 20,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Score falls well below the publish threshold due to zero insider buying, bearish options skew, lack of valuation discount, and active anti-signal gates (litigation, reimbursement concentration). With the stock up 58% YTD and insider selling at highs, the risk/reward for any structure is unfavorable.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 20,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Score falls well below the publish threshold due to zero insider buying, bearish options skew, lack of valuation discount, and active anti-signal gates (litigation, reimbursement concentration). With the stock up 58% YTD and insider selling at highs, the risk/reward for any structure is unfavorable.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 20,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Score falls well below the publish threshold due to zero insider buying, bearish options skew, lack of valuation discount, and active anti-signal gates (litigation, reimbursement concentration). With the stock up 58% YTD and insider selling at highs, the risk/reward for any structure is unfavorable.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 38360,
  "stop_reason": "stop",
  "completed_at": "2026-06-16T22:43:49.296Z"
}